Selank

Selank is a synthetic peptide derived from tuftsin and has been studied primarily in certain Eastern European settings for potential anxiolytic and cognitive effects.

Outside those regions, selank is typically discussed in experimental or wellness contexts rather than as part of mainstream psychiatric or neurology guidelines.

Proposed mechanisms for selank include modulation of GABAergic signaling, effects on monoamine pathways, and influences on neuropeptides and neurotrophic factors.

The extent to which these mechanisms translate into clinically meaningful outcomes remains under investigation.

In certain regional literature, selank has been explored in conditions related to anxiety and stress. Its regulatory approval and recommended uses, when present, are region-specific.

In many other jurisdictions, selank is not an approved medicine and is encountered in research or non-regulated markets.

Reported effects include local irritation (for nasal use) and nonspecific symptoms such as headache or fatigue. Long-term safety and interactions with other psychiatric therapies are not fully defined.

Selank is predominantly used as a nasal spray, though injectable forms exist. It is derived from the bioregulator Tuftsin.

These figures are community-sourced. No milligram or microgram dose for Selank appears in any English-indexed trial abstract or registry record, and Selank has no ClinicalTrials.gov entry — so the numbers above should be read as circulating practice, not as protocol-derived amounts.

The formulation studied clinically is an intranasal solution. Much of the material sold internationally is lyophilised powder marketed for reconstitution and subcutaneous injection — a route with no clinical trial behind it, and not the presentation the Russian trials evaluated.

Selank is frequently grouped with Semax, a separate peptide from the same Russian research programme derived from ACTH(4-10) rather than tuftsin. Shared origin is not shared pharmacology, and no trial has studied the two together.

Studies of selank have examined endpoints related to anxiety, mood, and cognitive performance, primarily in specific regional populations.

Extrapolating these findings to broader practice requires careful attention to study quality, populations, and comparators.

For deeper dives on this peptide, see:

• Selank benefits and areas of interest
• Selank side effects and safety context
• Selank dosing concepts (educational)
• Selank research and evidence overview

Is Selank approved anywhere? It is registered as a medicine in Russia, where it was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It has no FDA or EMA approval, and it has no entry on ClinicalTrials.gov.

How much human evidence is there? Very little, and it is all from one country. The foundational study compared Selank with the benzodiazepine medazepam in 62 patients with generalized anxiety disorder and neurasthenia, reporting similar anxiolytic effects plus antiasthenic and psychostimulant effects (Zh Nevrol Psikhiatr Im S S Korsakova 2008; PMID 18454096). A second trial compared it with phenazepam in 60 patients with phobic-anxiety and somatoform disorders (2014; PMID 25176261). Both used active comparators rather than placebo.

How does it work? Radioligand binding work shows Selank acts as a positive allosteric modulator of GABA binding, at a site that appears related to but not identical with the benzodiazepine site — it was able to block the modulatory activity of diazepam and olanzapine in that system (Protein & Peptide Letters 2018; PMID 30255741). That is a laboratory membrane study, not a demonstration of clinical mechanism.

Is it really non-addictive? That claim comes from short active-comparator trials in which Selank lacked the sedation and withdrawal profile of benzodiazepines. Absence of a dependence signal in a few weeks of study across roughly a hundred patients is not the same as demonstrated absence of dependence liability. The question is untested rather than answered.

What dose is used? No milligram or microgram figure appears in any English-indexed trial abstract or registry record. Duration is better documented — one companion study describes patients receiving Selank for 14 days (PMID 18577961). The microgram figures circulating online are community-sourced, not protocol-sourced.